Kołodziejczyk Milena, Kępka Lucyna, Tyc-Szczepaniak Dobromira, Wierzchowski Marek
Zakład Teleradioterapii, Centrum Onkologii-- Instytut im. Marii Skłodowskiej-Curie w Warszawie Kierownik: prof. dr hab. n. med. K. Bujko.
Pneumonol Alergol Pol. 2011;79(5):326-36.
In early stage non-small cell lung cancer (NSCLC) the stereotactic body radiation therapy (SBRT) gives promising results, similar to the results of surgical series. However, not all such patients are the candidates for this treatment method. The retrospective analysis of the results of three-dimensional conformal radiotherapy (3D-CRT) in stage I and II of NSCLC was undertaken, with a special focus on the patients who were candidates for SBRT treatment, but received 3D-CRT due to no access to the SBRT.
One hundred thirty-two consecutive stage I-II NSCLC patients who received radical 3D-CRT between 1998 and 2009 were included. Different radiotherapy schedules were used; thus the biologically equivalent doses (BED) were calculated for all. Sixty-eight patients met criteria of qualification for SBRT (peripheral T1-3N0 tumors with diameter £ 5 cm). Overall survival and local progression free survival (LPFS) were estimated for the whole group and compared for patients being and not being candidates for SBRT. Uni- and multivariate analyses were performed for prognostic factors.
Median BED value was 74 Gy (58-82 Gy). Patients who met SBRT criteria had significantly smaller gross tumor volume (GTV) comparing to the remainder (p 〈 0.00001). Three-year overall and local progression free survival rates were 37% and 50%, respectively. In comparison of SBRT candidates and others, only significant difference in three-year LPFS was obtained, 58% and 35%, respectively, p = 0.04. However, in the multivariate analysis, GTV, performance status, and stage were the only three prognostic factors for LPFS.
After 3D-CRT, superior local control for early stage NSCLC patients who met criteria of inclusion for SBRT in comparison with the remainder was demonstrated. However, this outcome was inferior to the local control after SBRT reported in the literature.
在早期非小细胞肺癌(NSCLC)中,立体定向体部放射治疗(SBRT)取得了令人鼓舞的结果,与手术治疗系列的结果相似。然而,并非所有此类患者都是这种治疗方法的候选者。对NSCLC I期和II期三维适形放疗(3D-CRT)的结果进行了回顾性分析,特别关注那些适合SBRT治疗但因无法接受SBRT而接受3D-CRT的患者。
纳入1998年至2009年间连续接受根治性3D-CRT的132例I-II期NSCLC患者。采用了不同的放疗方案;因此计算了所有患者的生物等效剂量(BED)。68例患者符合SBRT的入选标准(直径≤5 cm的外周T1-3N0肿瘤)。评估了整个组的总生存期和局部无进展生存期(LPFS),并比较了适合和不适合SBRT的患者。对预后因素进行了单因素和多因素分析。
BED中位数为74 Gy(58-82 Gy)。符合SBRT标准的患者与其余患者相比,肿瘤总体积(GTV)明显更小(p<0.00001)。三年总生存率和局部无进展生存率分别为37%和50%。比较适合SBRT的患者和其他患者,仅在三年LPFS方面存在显著差异,分别为58%和35%,p = 0.04。然而,在多因素分析中,GTV、体能状态和分期是LPFS仅有的三个预后因素。
3D-CRT后,符合SBRT纳入标准的早期NSCLC患者与其余患者相比,显示出更好的局部控制。然而,这一结果低于文献报道的SBRT后的局部控制效果。